Stephen Clyne, DO
Nephrology · Pontiac, MINPI 1235286055
Payments from drug & device makers
Across 225 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$731
- Vifor Pharma, Inc.$552
- Boehringer Ingelheim$396
- Otsuka America Pharmaceutical, Inc.$221
- Daiichi Sankyo Inc.$215
- Novo Nordisk$205
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,02596%
- Education$1884%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 33 | $731 |
| Vifor Pharma, Inc. | 41 | $552 |
| Boehringer Ingelheim | 22 | $396 |
| Otsuka America Pharmaceutical, Inc. | 13 | $221 |
| Daiichi Sankyo Inc. | 11 | $215 |
| Novo Nordisk | 5 | $205 |
| Bayer | 9 | $199 |
| Calliditas Therapeutics US Inc. | 9 | $196 |
| Amgen(2 entities) | 11 | $195 |
| Ardelyx, Inc. | 9 | $192 |
| Medtronic | 7 | $184 |
| Akebia Therapeutics Inc | 7 | $112 |
| Novartis | 5 | $111 |
| OPKO Pharmaceuticals, LLC | 6 | $96 |
| Travere Therapeutics, Inc. | 6 | $80 |
| GSK | 5 | $72 |
| Aurinia Pharma U.S., Inc. | 4 | $69 |
| AMAG Pharmaceuticals, Inc. | 4 | $60 |
| Bard Peripheral Vascular, Inc. | 2 | $44 |
| Mallinckrodt Enterprises LLC | 2 | $40 |
| Scpharmaceuticals Inc. | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Fresenius USA Marketing, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $19 |
| Merck | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Avenu Medical Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$125
How this compares
$4,213 in reported general payments places this provider in the 70th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 325 | $374,147 |
| FarxigaDapagliflozin Propanediol | 271 | $272,432 |
| InvokanaCanagliflozin | 38 | $47,451 |
| KerendiaFinerenone | 31 | $43,674 |
| MounjaroTirzepatide | 25 | $25,247 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $17,870 |
| Irbesartan | 299 | $8,650 |
| Nifedipine ErNifedipine | 122 | $5,623 |
| Potassium Citrate ErPotassium Citrate | 20 | $3,784 |
| Losartan Potassium | 191 | $3,059 |
| Calcitriol | 148 | $2,768 |
| Torsemide | 126 | $2,175 |
| Febuxostat | 12 | $2,156 |
| Bumetanide | 31 | $2,026 |
| Atorvastatin Calcium | 145 | $1,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $396 | $374,147325 claims |
| AstraZenecaFarxiga, Lokelma | $731 | $290,302282 claims |
| BayerKerendia | $199 | $43,67431 claims |
| Lilly USA, LLCMounjaro | $19 | $25,24725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 325 nephrology providers in Michigan.
Other nephrology in Pontiac
- Fahd Al-SaghirPontiac$3.9M
- Matthias KretzlerAnn Arbor$7.8M
- Kiran SaraiyaWarren$3.1M
- Alexander YevzlinAnn Arbor$1.3M
- Christopher ProvenzanoShelby Township$1.2M
- Joel TopfRoseville$1.1M
- Jennifer OdrenSaint Clair Shores$620K
- Zeenat BhatAnn Arbor$592K
- Ahmed AqeelKalamazoo$363K
- Claudia ZacharekSaginaw$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.